# Nuance Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuance-biotech

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.nuancebiotech.com
- Total disclosed funding: $268M
- Latest round: Series E (Jul 21, 2025)
- Investors on record: 8

## About

Founded in 2014 and based in Shanghai, China, Nuance Biotech Inc. operates as a specialty pharmaceutical company that focuses on the research and development of therapeutics. The company's products include Niferex for the treatment of iron deficiency anemia, Fibrin sealant (Human) FIBINGLURAAS for the treatment of the surface of burn and Treanda that supports Rituximab containing regimen.

## Funding rounds

- Series E, Jul 21, 2025, $42M — Changkejin  Investment, Beijing Konruns Pharmaceutical Co., Ltd., Shunxi Fund
- Series D, Dec 7, 2020, $181M — HBM Partners, RTW Investments, CBC Group, China Reform Holdings, MPC, Beijing Konruns Pharmaceutical Co., Ltd.
- Series C, Mar 22, 2019, $2M — HBM Partners
- Series B, Jun 27, 2018, $35M — HBM Partners, CBC Group
- Series A, May 1, 2017, $8M — MPC

## Investors

- MPC — Series A, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C, Series D
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series B, Series D
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series D
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series D
- Beijing Konruns Pharmaceutical Co., Ltd. — Series D, Series E
- Changkejin  Investment — Series E
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series E